Patent & Trade Mark
Ken Seidenman
Ken Seidenman

Level 14, 90 Collins St
Melbourne VIC 3000 AUSTRALIA
Tel +61 3 8618 4131
Fax +61 3 8618 4199
Recent Publications
06 Jul 2016
In line with President Obama’s recent call for a “Cancer Moonshot” (a US$1 billion initiative to achieve 10 years’ worth of cancer research in the next 5 years) the USPTO announced its “Cancer Immunotherapy Pilot Program” to accelerate examination of patent applications relating to cancer immunotherapy. The USPTO aims to complete patent examination for cancer immunotherapy applications under this program in 12 months or less.

11 May 2016
New guidelines issued from the USPTO provide some positive insight as to how claims to diagnostic methods will be examined for patent eligibility.

10 Feb 2015
Dr. Ken Seidenman discusses Patent-Eligible Subject Matter in the U.S. and how to best navigate the road ahead based on recent case law and the USPTO’s new interim guidelines on patent eligibility of “nature-based product" claims.

Ken is a Patent Attorney and registered US Patent Agent with broad technical expertise in molecular biology, neuroscience, stem cells, drug discovery platforms, antibodies, small molecule therapeutic methods and cancer therapeutics.

Having worked in a number of leading US law firms, Ken’s skills include preparation, prosecution and strategic counselling for biotechnology patent portfolio growth, while also assisting clients with evaluating patent validity, freedom to operate and due diligence matters.

His knowledge in drafting and prosecuting US and foreign patent applications, several of which covered high profile therapeutic platforms licensed to large, international corporations, means that he is well aware of the importance of intellectual property rights to an organisation’s corporate balance sheet.

Years of experience in managing patent portfolios and patent applications in the US has allowed Ken to develop a real understanding of clients IP needs, and allows him to assist clients to best utilise their Intellectual Property rights as part of their business plan. This work has been across multiple biotechnology areas, including stem cells, phenotypic drug screening platforms, recombinant protein therapeutics, small molecule therapeutic methods and diagnostic methods.

Prior to joining the patent profession, Ken was a postdoctoral fellow at Cold Spring Harbor Laboratory, with Roberto Malinow, where he studied the role of glutamate receptor trafficking in synaptic plasticity using a combination of electrophysiology, molecular biology, and imaging.



  • BSc Biochemistry & Molecular Biology from University of Wisconsin-Madison
  • PhD Neuroscience from Northwestern University
  • Post-Doctoral Fellow at Cold Spring Harbor Laboratory
  • Masters of Intellectual Property Law from The University of Melbourne

Key Areas of Expertise

  • Stem Cells
  • CRISPR platform genome editing methods and compositions
  • Therapies including small molecule drugs, antibodies, proteins, peptides, nucleic acids, and cell therapies
  • Diagnostics including cancer and neurodegenerative disease biomarkers
  • Drug-screening platforms
  • Neuroscience
  • Cell culture and scale up methods and reagents
  • Metabolic engineering (e.g., for biosynthesis of biofuels and high value secondary metabolites)
  • Transgenic organisms including animals and microorganisms
  • Gene targeting, gene knockdown, and CRISPR methods
  • Tissue engineering
  • Transfection methods (in vitro and in vivo)
  • Nanoparticle-based drug delivery
  • Gene expression profiling
  • Proteomics

Industry Focus

Professional Affiliations

  • Registered U.S. Patent Agent
  • Member of AusBiotech